CSF neurofilament levels: A potential prognostic marker in Guillain–Barré syndrome
Authors:
- A. PetzoldAPA. Petzold
- N. HindsNHN. Hinds
- Nm F. MurrayNMNm F. Murray
- N. P. HirschNHN. P. Hirsch
- D. GrantDGD. Grant
- G. KeirGKG. Keir
- E. J. ThompsonETE. J. Thompson
- M. M. ReillyMRM. M. Reilly
- 26 September 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 67 (6) , 1071-1073
Abstract
Long-term morbidity from Guillain–Barré syndrome (GBS) is caused by axonal damage. This prospective study demonstrated that neurofilaments (NfHs), a biomarker for axonal damage, were of prognostic value in GBS. CSF NfH levels correlated with the F score and Medical Research Council summed score and were higher in patients with neurophysiologic evidence of axonal degeneration compared to those without. Pathologically high CSF NfH levels (>0.73 ng/mL) predicted worse motor and functional outcome.Keywords
This publication has 9 references indexed in Scilit:
- Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and lossJournal of the Neurological Sciences, 2005
- A specific ELISA for measuring neurofilament heavy chain phosphoformsJournal of Immunological Methods, 2003
- Quality of life complements traditional outcome measures in immune-mediated polyneuropathiesNeurology, 2002
- Early Electrodiagnostic Findings in Guillain-Barré SyndromeArchives of Neurology, 2001
- Long-term outcome in patients with Guillain–Barré syndrome requiring mechanical ventilationNeurology, 2000
- Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcomeAnnals of Neurology, 1998
- Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndromeThe Lancet, 1997
- Assessment of current diagnostic criteria for Guillain-Barr syndromeAnnals of Neurology, 1990
- Acquired inflammatory demyelinating polyneuropathies: Clinical and electrodiagnostic featuresMuscle & Nerve, 1989